JP2013536240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536240A5 JP2013536240A5 JP2013526099A JP2013526099A JP2013536240A5 JP 2013536240 A5 JP2013536240 A5 JP 2013536240A5 JP 2013526099 A JP2013526099 A JP 2013526099A JP 2013526099 A JP2013526099 A JP 2013526099A JP 2013536240 A5 JP2013536240 A5 JP 2013536240A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- composition according
- epha2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37658210P | 2010-08-24 | 2010-08-24 | |
| US61/376,582 | 2010-08-24 | ||
| PCT/US2011/048823 WO2012027379A2 (en) | 2010-08-24 | 2011-08-23 | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139885A Division JP6511021B2 (ja) | 2010-08-24 | 2016-07-15 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536240A JP2013536240A (ja) | 2013-09-19 |
| JP2013536240A5 true JP2013536240A5 (enExample) | 2014-10-02 |
Family
ID=45724024
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526099A Pending JP2013536240A (ja) | 2010-08-24 | 2011-08-23 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2016139885A Active JP6511021B2 (ja) | 2010-08-24 | 2016-07-15 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2019072379A Active JP6931240B2 (ja) | 2010-08-24 | 2019-04-05 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2021129288A Active JP7793167B2 (ja) | 2010-08-24 | 2021-08-05 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
| JP2023146554A Withdrawn JP2023175764A (ja) | 2010-08-24 | 2023-09-08 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139885A Active JP6511021B2 (ja) | 2010-08-24 | 2016-07-15 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2019072379A Active JP6931240B2 (ja) | 2010-08-24 | 2019-04-05 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2021129288A Active JP7793167B2 (ja) | 2010-08-24 | 2021-08-05 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
| JP2023146554A Withdrawn JP2023175764A (ja) | 2010-08-24 | 2023-09-08 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20120052080A1 (enExample) |
| EP (3) | EP2608799B1 (enExample) |
| JP (5) | JP2013536240A (enExample) |
| AU (1) | AU2011293522B2 (enExample) |
| CA (2) | CA3066981A1 (enExample) |
| DK (1) | DK2608799T3 (enExample) |
| ES (2) | ES2722799T3 (enExample) |
| MX (1) | MX353165B (enExample) |
| WO (1) | WO2012027379A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| WO2007047764A2 (en) | 2005-10-17 | 2007-04-26 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| US8097256B2 (en) * | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US9068020B2 (en) * | 2008-09-02 | 2015-06-30 | Cedars-Sinai Medical Center | CD133 epitopes |
| WO2012027379A2 (en) | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| HK1204261A1 (en) | 2012-01-13 | 2015-11-13 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| ES2973957T3 (es) * | 2012-03-19 | 2024-06-25 | Stemline Therapeutics Inc | Métodos para tratar y monitorizar el estado de un cáncer |
| WO2013148649A1 (en) | 2012-03-26 | 2013-10-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| SMT202100545T1 (it) * | 2012-05-16 | 2021-11-12 | Stemline Therapeutics Inc | Vaccini contro il cancro mirati alle cellule staminali cancerose |
| SG11201500903XA (en) * | 2012-08-07 | 2015-03-30 | Genentech Inc | Combination therapy for the treatment of glioblastoma |
| RU2670488C2 (ru) | 2012-09-13 | 2018-10-23 | Юниверсите Де Женев | Новые проникающие в клетку пептиды |
| WO2014070663A1 (en) * | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| CN103961702B (zh) * | 2013-02-05 | 2019-04-09 | 日东电工株式会社 | 粘膜给予用wt1肽癌症疫苗组合物 |
| WO2014127296A1 (en) * | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Cancer vaccines and vaccination methods |
| PL2970492T3 (pl) | 2013-03-15 | 2019-10-31 | Univ Wake Forest Health Sciences | Przeciwciała przeciwko ludzkim i psim il-13ra2 |
| CA2908042C (en) * | 2013-03-27 | 2023-01-31 | Immunovaccine Technologies Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
| WO2014200969A2 (en) * | 2013-06-10 | 2014-12-18 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| CN106132432A (zh) * | 2013-12-06 | 2016-11-16 | 博德研究所 | 用于瘤形成疫苗的配制品 |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| CN103768595B (zh) * | 2014-01-27 | 2016-03-02 | 中国医学科学院医学生物学研究所 | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 |
| WO2016011052A1 (en) | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| EP4636401A2 (en) | 2014-12-19 | 2025-10-22 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
| LT3429618T (lt) | 2016-03-16 | 2024-05-10 | Amal Therapeutics Sa | Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje |
| WO2018055060A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
| CN110049774A (zh) * | 2016-10-07 | 2019-07-23 | 恩特罗姆公司 | 肿瘤相关抗原表位的小型生物群序列变体 |
| IL302345B2 (en) | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| WO2018065625A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Immunogenic compounds for cancer therapy |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| KR102823291B1 (ko) * | 2017-10-09 | 2025-06-19 | 엔터롬 에스.에이. | 종양-관련된 항원 에피토프의 미생물 서열 변이체 |
| JP2018070629A (ja) * | 2017-11-28 | 2018-05-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | がんの処置におけるサバイビンワクチンの有効性を向上させるための方法 |
| CN107903305B (zh) * | 2017-12-25 | 2020-11-13 | 陕西慧康生物科技有限责任公司 | 一种固液联合合成地索莫泰的方法 |
| US20210106652A1 (en) * | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| SI3773689T1 (sl) * | 2018-04-11 | 2023-02-28 | Enterome S.A. | Antigenski peptidi za preprečevanje in zdravljenje raka |
| WO2021025005A1 (ja) * | 2019-08-05 | 2021-02-11 | 国立大学法人佐賀大学 | 中空コラーゲンゲル |
| DE102019214359A1 (de) * | 2019-09-20 | 2021-03-25 | Siemens Healthcare Gmbh | Verfahren zu einer adaptiven Ansteuerung eines Magnetresonanzgerätes |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA117152A (en) | 1908-12-04 | 1909-03-09 | George A. Stebbins | Sulphur burner |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US6419931B1 (en) | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| JPH07502496A (ja) | 1991-10-07 | 1995-03-16 | バイオゲン インコーポレイテッド | Ｃｄ２／ｌｆａ−３相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法 |
| FI972514L (fi) | 1994-12-14 | 1997-08-12 | Scripps Research Inst | Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US20020012946A1 (en) | 2000-02-23 | 2002-01-31 | Luiz Belardinelli | Method of identifying partial agonists of the A2A receptor |
| AU2002322478A1 (en) | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| IL157706A0 (en) | 2001-03-02 | 2004-03-28 | Medimmune Inc | METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| EP1613273B1 (en) | 2003-04-11 | 2012-06-13 | MedImmune, LLC | Recombinant il-9 antibodies and uses thereof |
| PT1620456E (pt) * | 2003-04-18 | 2014-04-15 | Biotech Synergy Inc | Péptidos antigénicos hla-a2 associados a tumor e suas composições |
| JP2004353820A (ja) | 2003-05-30 | 2004-12-16 | Toyota Motor Corp | トリポート型等速ジョイント部品およびトリポート型等速ジョイント |
| US20050048550A1 (en) | 2003-07-30 | 2005-03-03 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | EphA2 T-cell epitope agonists and uses therefor |
| IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| EP1682173A4 (en) * | 2003-10-15 | 2007-10-31 | Medimmune Inc | EPHA2 VACCINE ON LISTERIA BASE |
| US7842294B2 (en) * | 2003-11-19 | 2010-11-30 | Survac Aps | Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients |
| US7488718B2 (en) * | 2003-12-01 | 2009-02-10 | Sloan Kettering Institue For Cancer Research | Synthetic HLA binding peptide analogues and uses thereof |
| US20050153923A1 (en) | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
| WO2005067460A2 (en) | 2003-12-24 | 2005-07-28 | Medimmune, Inc. | Epha2 vaccines |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| JP5087925B2 (ja) | 2004-12-07 | 2012-12-05 | 東レ株式会社 | 新規癌抗原ペプチド及びその用途 |
| WO2007047764A2 (en) * | 2005-10-17 | 2007-04-26 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| US8097256B2 (en) * | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| WO2009012460A1 (en) | 2007-07-19 | 2009-01-22 | Health Research, Inc. | Survivin peptides as cancer vaccines |
| CA2940962C (en) * | 2007-12-05 | 2018-07-24 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| US8728806B2 (en) * | 2008-12-06 | 2014-05-20 | The Board Of Regents, The University Of Texas System | Methods and compositions related to Th-1 dendritic cells |
| US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| WO2012027379A2 (en) * | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
-
2011
- 2011-08-23 WO PCT/US2011/048823 patent/WO2012027379A2/en not_active Ceased
- 2011-08-23 CA CA3066981A patent/CA3066981A1/en active Pending
- 2011-08-23 MX MX2013002207A patent/MX353165B/es active IP Right Grant
- 2011-08-23 EP EP11820530.1A patent/EP2608799B1/en active Active
- 2011-08-23 CA CA2809362A patent/CA2809362C/en active Active
- 2011-08-23 DK DK11820530.1T patent/DK2608799T3/en active
- 2011-08-23 AU AU2011293522A patent/AU2011293522B2/en active Active
- 2011-08-23 ES ES11820530T patent/ES2722799T3/es active Active
- 2011-08-23 JP JP2013526099A patent/JP2013536240A/ja active Pending
- 2011-08-23 ES ES18211075T patent/ES2930809T3/es active Active
- 2011-08-23 EP EP22193769.1A patent/EP4159226A1/en active Pending
- 2011-08-23 EP EP18211075.9A patent/EP3511013B1/en active Active
- 2011-08-23 US US13/215,938 patent/US20120052080A1/en not_active Abandoned
-
2013
- 2013-06-24 US US13/925,093 patent/US20130295046A1/en not_active Abandoned
-
2014
- 2014-10-16 US US14/515,939 patent/US20150258185A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/724,127 patent/US10874730B2/en not_active Expired - Lifetime
-
2016
- 2016-07-15 JP JP2016139885A patent/JP6511021B2/ja active Active
-
2019
- 2019-04-05 JP JP2019072379A patent/JP6931240B2/ja active Active
-
2020
- 2020-12-02 US US17/109,463 patent/US20210338790A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021129288A patent/JP7793167B2/ja active Active
-
2023
- 2023-09-08 JP JP2023146554A patent/JP2023175764A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536240A5 (enExample) | ||
| Ho et al. | Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? | |
| Li et al. | Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy | |
| JP2016539946A5 (enExample) | ||
| Zhang et al. | PH-controlled release of antigens using mesoporous silica nanoparticles delivery system for developing a fish oral vaccine | |
| Müller et al. | Inflammation, immunity, and vaccine development for Helicobacter pylori | |
| JP2013536157A5 (enExample) | ||
| JP2013530157A5 (enExample) | ||
| JP2012021028A5 (enExample) | ||
| JP2015110588A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| JP2012522837A5 (enExample) | ||
| JP2019531293A5 (enExample) | ||
| Saung et al. | Particulate carrier systems as adjuvants for cancer vaccines | |
| JP2012001565A5 (enExample) | ||
| Moreno-Mendieta et al. | A novel antigen-carrier system: The Mycobacterium tuberculosis Acr protein carried by raw starch microparticles | |
| JP2012500184A5 (enExample) | ||
| JP2011525902A5 (enExample) | ||
| JP2016521754A5 (enExample) | ||
| JP2006502228A5 (enExample) | ||
| Rong et al. | Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine | |
| JP2014139185A5 (enExample) | ||
| Zhang et al. | Polymer–protein core–shell nanoparticles for enhanced antigen immunogenicity |